Estrogens plus raloxifene on endometrial safety and menopausal symptoms—semisystematic review

  title={Estrogens plus raloxifene on endometrial safety and menopausal symptoms—semisystematic review},
  author={Andrea L{\'u}cia Bastos Carneiro and Rita de C{\'a}ssia de Maio Dardes and Mauro Abi Haidar},
  journal={Menopause: The Journal of The North American Menopause Society},
Objective The aim of this study was to summarize the evidence of endometrial safety and quality of life assessment in postmenopausal women taking raloxifene (RLX) + estrogens (E). Methods Clinical studies reporting RLX + E were identified using Medline and LILACS and through reviewing reference lists of highly significant publications. Articles published in Portuguese, Spanish, and English from the past 10 years were considered. Results Six corresponding clinical trials were identified… 
Effects of Raloxifene Combined with Low-dose Conjugated Estrogen on the Endometrium in Menopausal Women at High Risk for Breast Cancer
Combined raloxifene and low-dose CE decreased the severity of menopausal symptoms to a similar extent as CE alone and had similar effects as ral oxifene alone on the endometrium.
Selective estrogen receptor modulator with estrogen does not affect the proliferation and apoptosis of uterine leiomyoma cells
SERM combined with estrogen may have a better safety for perimenopausal women with uterine leiomyoma in MHT.
Effects of a Chinese medicinal plant Radix astragali on the ovariectomized female rats.
It is concluded that RA can significantly improve the immune functions of the ovariectomized female rats, although it cannot change the sex hormones levels as significantly as estrogen.
Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence
Available evidence indicates that ospemifene has unique effects on tissue, leading to a favorable long-term profile for the relief of vulvar and vaginal atrophy compared with other estrogen receptor agonists/antagonists with no short-term concerns about endometrial safety.


The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety
In women transitioning from estrogen-progestin therapy, occurrence of vasomotor symptoms was unchanged from baseline with RLX treatment, but these symptoms were significantly reduced with combined RLX + E therapy.
Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women
Concomitant administration of raloxifene does not alter the effects of the 17&bgr;-estradiol ring on alleviating signs and symptoms of genitourinary atrophy in postmenopausal women.
Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses.
The treatment that is proposed in this study can constitute a temporary alternative during the period of transition from HT to raloxifene in the control of climacteric symptoms.
Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium—a pilot study
Gradual conversion to raloxifene from low-dose estrogen, with a progression from 60 mg every alternate day to 60 mg/day, is a viable option in potentially symptomatic, postmenopausal women.
Novel agents to modulate oestrogen action.
The SERMs have evolved from mere laboratory curiosities into drugs that hold promise for preventing several major diseases associated with ageing in women, including breast cancer, osteoporosis and cardiovascular disease in postmenopausal women.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistically significant higher risk of noninvasive breast cancer.
Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice.
Treatment with raloxifene following 5 years of adjuvant tamoxifen may not further decrease breast cancer recurrence and may increase endometrial cancer incidence.